Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of DALAVIR vs TIVICAY + EPIVIR + VIREAD in Healthy Subjects Under Fasting Conditions
TCTR20220331004Phase 1Not yet recruiting
- Sponsor
- Government Pharmaceutical Organization
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir, lamivudine and tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Government Pharmaceutical Organization. Planned start May 2022; status: not yet recruiting.
02
Drugs
dolutegravirlamivudinetenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20220331004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220331004.